Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma-Reference-Cited by-同舟云学术

Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma

Published:2015-10-16 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Lee Kyung-Hun,Lee Kyoung-Bun,Kim Tae-Yong,Han Sae-Won,Oh Do-Youn,Im Seock-Ah,Kim Tae-You,Yi Nam-Joon,Lee Kwang-Woong,Suh Kyung-Suk,Jang Ja-June,Bang Yung-Jue

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-015-1737-4.pdf

Reference36 articles.

1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806–13.

2. Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol. 2014;49(2):165–72.

3. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg. 2008;32(12):2675–80.

4. Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010;17(4):455–62.

5. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137(4):396–402.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics;Frontiers in Chemistry;2024-07-29

2. Emerging Therapies in Management of Cholangiocarcinoma;Cancers;2024-01-31

3. Intrahepatic Cholangiocarcinoma - Where Do We Stand Today? Literature Review;CHIRURGIA-BUCHAREST;2023

4. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer;Journal of Biomolecular Structure and Dynamics;2023-05-30

5. ROS1-positive non-small-cell lung cancer;Cancer Research, Statistics, and Treatment;2022-07